Table: Santen Pharm -9-MTH group results (IFRS)
06/02/2018 06:00
Feb 6 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2017 Dec 31, 2016 Mar 31, 2018
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 168.59 150.67 224.00
(+11.9 pct) (+1.0 pct) (+12.5 pct)
Operating 30.09 27.49 37.40
(+9.5 pct) (-63.1 pct) (+15.2 pct)
Pretax 29.54 23.92 37.70
(+23.5 pct) (-67.9 pct) (+25.4 pct)
Net 27.33 17.16 32.10
(+59.2 pct) (-65.6 pct) (+47.7 pct)
EPS Basic 67.27 yen 41.69 yen 79.03 yen
EPS Diluted 67.02 yen 41.53 yen
Ann Div 26.00 yen 26.00 yen
-Q2 Div 13.00 yen 13.00 yen
-Q4 Div 13.00 yen 13.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T
((Tokyo Headline News Desk +813 6441 1812))